Apremilast: Extension study data

Data from 126 patients enrolled in a 12-week extension study of a 12-week, double-blind, international Phase II trial (CC-10004-PSA-001) showed that twice-daily 20 mg and once-daily 40 mg apremilast improved ACR20 at week 24 by 40% and 39.1%, respectively. The 86 patients who continued twice-daily 20 mg and once-daily 40 mg apremilast had ACR50 of 20% and 23.9%, respectively, and ACR70 of 15% and 13%, respectively. The 40 patients who switched to twice-daily 20 mg and once-daily 40 mg apremilast from placebo had ACR20 of 35% and 40%, respectively. Data were presented at the American College of Rheumatology meeting in Philadelphia. ...